Deep Tech in Pharma Revolution.
AI Drug DiscoveryBiotechnology TrendsDeep Tech InvestmentGenomics in PharmaPharmaceutical InnovationRisk Mitigation
The report explores the significant impact of deep technologies such as AI, genomics, and biomanufacturing on the pharmaceutical industry. It highlights how AI is accelerating drug discovery, reducing timelines, and saving costs, while genomics and multi-omics platforms are advancing personalized medicine. The report also delves into the evolution of biomanufacturing, focusing on sustainability and efficiency. It provides insights into global investment trends, regulatory challenges, and the competitive landscape, offering a comprehensive guide for stakeholders in the pharmaceutical and biotech sectors.
Celso Gomes, Ghost Research
October 2025
Perspective.
PurposeTo analyze the integration and impact of deep technologies in the pharmaceutical industry, highlighting trends, opportunities, and challenges.
AudienceIndustry stakeholders, investors, pharma and biotech professionals, and policymakers.
Special EmphasisInnovation, sustainability, AI governance, regulatory challenges.
56Pages of Deep Analysis
195Curated Credible Sources
1Proprietary AI Visuals
3Data Analysis Tables
$495
Celso Gomes
10+ Years of Experience
Sectors & Industries
IndustrialsConsumer Staples
Functions & Expertise
Market IntelligenceConsumer & Retail
Have questions? Our Research Desk is here to help
Top Insights.
AI-driven technologies can reduce drug development timelines by up to 40%.Genomics and CRISPR are leading to significant advancements in personalized medicine.Biomanufacturing is being transformed by AI-enabled process optimization and modular systems.The investment in deep tech pharma is projected to rise sharply, necessitating robust ROI monitoring.Collaborative models and regional clusters drive innovation and regulatory support.Key Questions Answered.
56Pages of Deep Analysis
1Proprietary AI Visuals
195Curated Credible Sources
3Data Analysis Tables
Summary.
